Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Julphar
Federal Trade Commission
Healthtrust
Queensland Health
Boehringer Ingelheim
Chinese Patent Office
QuintilesIMS
Argus Health

Generated: January 23, 2018

DrugPatentWatch Database Preview

ANGIOMAX Drug Profile

« Back to Dashboard

Which patents cover Angiomax, and when can generic versions of Angiomax launch?

Angiomax is a drug marketed by The Medicines Co and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ANGIOMAX is bivalirudin. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.

US Patents and Regulatory Information for ANGIOMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
The Medicines Co ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
The Medicines Co ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ANGIOMAX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe For Injection 250 mg/vial ➤ Subscribe 9/1/2009

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Moodys
Johnson and Johnson
Boehringer Ingelheim
Covington
McKesson
Daiichi Sankyo
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot